ReviewReviews in endocrine & metabolic disorders2016
Determinants of mortality in patients with type 2 diabetes: a review.
Review in Reviews in endocrine & metabolic disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.Diabetes, obesity & metabolism · 2025Trial
- Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study).Frontiers in endocrinology · 2024Trial
- Low BMI predicts mortality in T2DM older adults: cholesterol parameters demonstrate negative mediation.Diabetology & metabolic syndrome · 2026Article
- Trends in Depression Among Hospitalized Patients with Type 2 Diabetes in Spain (2017-2023): A Population-Based Analysis with a Focus on Sex Differences and In-Hospital Outcomes.Journal of clinical medicine · 2025Article
- Health-related quality of life in populations with diabetes, prediabetes, and normal glycemic levels in Guangzhou, China: a cross-sectional study.Frontiers in endocrinology · 2025Observational
- Factors Associated With Receipt of Diabetes Self-Management Education and Support for Type 2 Diabetes: Potential for a Population Health Management Approach.Journal of diabetes science and technology · 2023Article
- Gold Nanoparticles Supported on Ceria Nanoparticles Modulate Leukocyte-Endothelium Cell Interactions and Inflammation in Type 2 Diabetes.Antioxidants (Basel, Switzerland) · 2022Article
- Sex-Related Disparities in the Prevalence of Depression among Patients Hospitalized with Type 2 Diabetes Mellitus in Spain, 2011-2020.Journal of clinical medicine · 2022Article
- Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance.Communications biology · 2021Article
- Treatment Effect of Type 2 Diabetes Patients in Outpatient Department Based on Blockchain Electronic Mobile Medical App.Journal of healthcare engineering · 2021Article
- Secular trends in smoking in relation to prevalent and incident smoking-related disease: A prospective population-based study.Tobacco induced diseases · 2019Article
- Visual impairment and mortality in patients with type 2 diabetes.BMJ open diabetes research & care · 2019Article
- The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.Scientific reports · 2018Article
- Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy.Canadian journal of gastroenterology & hepatology · 2018Review
- Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.Canadian journal of gastroenterology & hepatology · 2018Observational
- Relationships of circular RNA with diabetes and depression.Scientific reports · 2017Article
- Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.The pharmacogenomics journal · 2016Review
- Introduction to Hanefeld Symposium: 40+ years of metabolic syndrome.Reviews in endocrine & metabolic disorders · 2016Article
- Bringing patient centricity to diabetes medication access in Canada.ClinicoEconomics and outcomes research : CEOR · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledWe aimed to review and summarize the evidence from accomplished trials analyzing factors influencing mortality in patients with T2DM and to provide some recommendations for targets and treatment in the European region. The following databases were searched for relevant trials: PubMed and the Cochrane Library. Of 3.806 citations, 134 trials met our inclusion criteria.
resultsThe reduction in lifetime for 65 + -years-old patients having less than 10 years T2DM amounts to 1.8 years. Having T2DM for more than 10 years lifetime will be reduced by 2.7 years. However, the lifetime shortening factor of T2DM will even be stronger for 40 + -years-old patients at onset. Males will lose 11.6 years of life and 18.6 QUALYs. T2DM among females will reduce life by 14 QUALYs by 22 years. From a statistical point of view, the highest mortality rate will occur in an over 55-years-old European smoking and non-compliant diabetic woman with alcohol abuse living in a rural area with a low level of education and a low socio-economic status. Furthermore, other co-morbidities such as cardiovascular diseases, gout, and depression affect mortality. Additionally, mortality will increase with a BMI over 35 and also with a BMI under 20-25. This refers to the obesity paradox indicating a higher mortality rate among normal weight patients with T2DM compared to overweight patients with T2DM. HbA1c-levels between 6.5 % and 7 % are associated with the lowest impact on mortality.
Indexed as
Identifiers
27068710What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.